Recent Finacing
Recent Raise
EpicentRx develops RRx-001, a CD47–SIRPα–targeting small-molecule immunotherapy in multiple clinical trials, and a transgene-armed oncolytic adenoviral platform including a TGF‑beta trap candidate.
Focus Areas
Total Raised
Funding round
See the team members at EpicentRx Inc.
